Myricx Bio (Myricx Pharma Ltd.) and Wuxi Biologics Co. Ltd. have entered into a license agreement under which Myricx will have exclusive access to a proprietary antibody that was discovered based on Wuxi Bio's integrated technology platforms.
Immvira Group Co. plans to progress its intravenous oncolytic herpes simplex virus (oHSV) MVR-T3011-IV to phase II trials after completing a phase I study in the U.S. in patients with late-stage solid tumors. The Shenzhen, China-based company is the first to conduct clinical trials via intravenous administration of oHSVs.
Immvira Group Co. plans to progress its intravenous oncolytic herpes simplex virus (oHSV) MVR-T3011-IV to phase II trials after completing a phase I study in the U.S. in patients with late-stage solid tumors. The Shenzhen, China-based company is the first to conduct clinical trials via intravenous administration of oHSVs.
Researchers from Tscan Therapeutics Inc. presented preclinical data for TSC-200-A0201, a naturally occurring HPV16 E7-specific T-cell receptor (TCR) T-cell therapy discovered using Tscan’s proprietary Receptorscan platform. It is being developed for the treatment of human papillomavirus 16 (HPV16)-positive solid tumors. The therapeutic TCR in TSC-200-A0201 was introduced into a transposon vector, with the resulting TCR T therapy product being a mixture of cytotoxic and helper T cells, both reprogrammed to recognize HPV16+ HLA-A*02:01+ cells.
Abbisko Therapeutics Co. Ltd. has received clearance from China's National Medical Products Administration (NMPA) to conduct clinical trials in China of ABSK-051, a novel small-molecule CD73 inhibitor, for advanced solid tumors.
Researchers from Chugai Pharmaceutical Co. Ltd. presented preclinical data of SAIL-66, a trispecific antibody targeting Claudin-6 (CLDN6), CD137 (4-1BB) and CD3, for cancer immunotherapy.
Abbisko Therapeutics Co. Ltd. has received FDA clearance of its IND application for ABSK-012, a highly selective small-molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4), for advanced solid tumors.
CSPC Pharmaceutical Group Ltd.’s SYS-6011 has been cleared by China’s National Medical Products Administration (NMPA) to enter clinical trials in China for solid tumors.
Angiex Inc. has received FDA clearance of its IND application for AGX-101, a novel TM4SF1-directed antibody-drug conjugate (ADC) being developed for the treatment of solid cancers.
